Statement

Name of the Drug	Name of the drug Company	Indications
1. Triprolidine	M/s. Borroughs Wellcome, Bombay.	Nasal and respiratory, congestion, common Cold, hey fever, sinusitis elergic and Vasemeter rhinitis.
2. Polymixin-B	M/s. Berroughs Wellcome, Bombay.	Aotibacterial
	M/s. Fairdeal Corporation, Bombay.	
3. Glipizide	M/s. U.S. Vitamins, Bombay.	Diabitis.

Inclusion of Diphtheria, Tetanus and Triple Antigen under Drug Price Control Order

742. CHOWDHARY RAM SEWAK: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether his Ministry had recommended for inclusion of Diphtheria Tetanus and Triple Antigen under First Schedule of Drugs Price Control Order;

(b) whether the country has attained self-sufficiency in these products;

(c) whether Kelkar Committee has admitted that there is a surplus production thereof;

(d) whether it is also a fact that price of these vaccines have gone up by around 200 per cent.;

(e) whether it is a fact that these vaccines are used under Immunization programme; and

(f) if so, what are the reasons for non-inclusion of these vaccines under First Schedule and what steps have been taken to cover them as per Policy statement?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI (SAROJ KHAPARDE): (a) Yes, Sir.

(b) and (c) The supplementary report of the Kelkar Committee has opined that although in case of certain vaccines there are surplus production, in future, it is anticipated that biotechnological methods, which are capital intensive would replace the outdated technology.

(d) The pricing of vaccines|drugs is monitored by the Department of Chemicals and Petro-Chemicals.

(e) Yes, Sir.

(f) The reasons given in the supplementary report of the Kelkar Committee for exclusion of vaccines and Sera from the purview of price control is to motivate Indian Entreprenures to adopt newer methods of productions which are capital intensive.

Shifting the category of drugs produced from intermediate stage

743. CHOWDHARY RAM SEWAK: SHRI M. KADHARSHA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Government are aware that Rifampicin is being produced from intermediate stage;

(b) whether it is a fact that this drug is needed for National Health Programme;

(c) whether it is also a fact that according to policy statement drugs needed for National Health Programmes would be covered under Category—I;

(d) if so, whether his Ministry took the approval of the Cabinet for shifting the category; and

(e) what are the reasons and the circumstances under which his ministry did not recommend to Kelkar Committee to shift the category of all drugs being produced from intermediate stage?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) Yes, Sir.

(b) Yes, Sir.

(c) Yes, Sir.

(d) Representation for re-categorisation of Rifampicin received by the Ministry were examined and recommendations were sent to the Deptt. of Chemicals and Petrochemicals for consideration as that Department in consultation with the Kelkar Committee is the final authority for categorisation and re-categorisation.

(e) No other representation for such re-classification was received.

Inclusion of Sodium Sulphacetamide under First Schedule of Drug Price Control Order

744. CHOWDHARY RAM SEWAK: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether his Ministry had recommended for inclusion of Sodium Sulphacetamide under First Schedule of Drug Price Control Order on the ground of Trachoma Control Programme;

(b) whether it is a fact that Kelkar Committee had recommended for shifting of this drug to the second schedule;

(c) if so, whether his Ministry was consulted before making such recommendation; and

(d) if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) and (b) Yes, Sir.

(c) and (d) Although Ministry of Health and Family Welfare was not consulted, Kelkar Committee which had finally opined on recategorisation of Sodium Sulphacetamide, had two members representing Ministry of Health and Family Welfare. The Technical reasons which weighted with Kelkar Commiitee for re-categorisation of Sodium Sulphacetamide is that the drug is not a specific Anti-Trachoma agent.

Clearance of Haloperidol and Thioridazine for marketing in India

745. CHOWDHARY RAM SEWAK: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that Haloperidol and Thioridazine have been cleared for marketing in India;

(b) if so, what are the indications for which each of these drugs were cleared;

(c) what are the names of five leading brands under which each of these drugs is being marketed alongwith the strength and the composition of each;

(d) whether any of these drugs is being imported in the country; and

(e) if so, the quantity imported of each during the last two years, yearwise, alongwith CIF value of import each year?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) Yes, Sir.